Purpose. The efficacy and safety of granulocyte colony-stimulating factor (G-CSF) in critically ill patients with severe sepsis or septic shock were evaluated. Summary. The medical literature was ...

At the moment, WHIM patients are treated off-label with injectable G-CSF or GM-CSF drugs like filgrastim or sargramostim to combat neutropenia, or receive immunoglobulin replacement therapy ...

The company had sought approval of plinabulin for the prevention of chemotherapy-induced neutropenia (CIN) in combination with granulocyte colony-stimulating factor (G-CSF) drug pegfilgrastim ...

The European Organisation for Research and Treatment of Cancer (EORTC) has recently produced guidelines for the use of G-CSF in adults with lymphomas and solid tumors undergoing chemotherapy.

The donor is administered the growth factor G-CSF for five days. This drug increases the number of stem cells in the peripheral blood, which are then obtained directly from the blood using a ...

Luveltamab tazevibulin demonstrated activity in an ongoing phase 2/3 trial of patients with FRα-positive, platinum-resistant ovarian cancer.

Pexegra TM is a long-acting G-CSF biosimilar indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving ...

Clinical studies examining the use of G-CSF in critically ill patients without hematologic disease and immunosuppression included mostly patients with severe sepsis and septic shock. These studies ...